The new sepsis consensus definitions (Sepsis-3): the good, the not-so-bad, and the actually-quite-pretty by Singer, M
 The new sepsis consensus definitions (Sepsis-3): the good, 
the not-so-bad, and the actually-quite-pretty 
Mervyn Singer 
 
I thank Drs. Sprung, Schein and Balk [1] for airing their concerns and encouraging debate; hopefully I 
can offer a persuasive rebuttal. 
While we lack absolute answers to define and characterize sepsis, our understanding has advanced 
considerably. The excessive prior focus on ‘systemic inflammation’ has led to the multiple drug trial 
failures. 
The imprecise characterization of “organ dysfunction” and “shock” in previous Consensus Definitions 
[2] has produced huge disparities in reported incidence and outcomes. Septic shock incidence varies 
tenfold and mortality fourfold [3]. “Severe sepsis” coded in a nationwide hospital sample in the USA 
rose from 300,270 to 781,725 within 8 years, with mortality nearly doubling [4]. This highlights the 
failure of current epidemiology to accurately assess the impact of sepsis. 
The Sepsis-3 Task Force carefully balanced the desire to update definitions and offer robust, data-
based clinical criteria against the necessary upheaval caused by usurping old friends (‘SIRS’, ‘severe 
sepsis’) and introducing a new lexicon [5]. Our improved knowledge base and the above examples 
stress the imperative for change. 
Differentiating sepsis (infection-related organ dysfunction) from non-life-threatening mild infection is 
acknowledged as ‘good’. Patients cannot die from infection without organ failure. Excessive overlap 
existed between infection and sepsis defined by the SIRS criteria. Ergo, ‘new’ sepsis describes a sicker 
patient, making ‘severe sepsis’ redundant. 
Why was SIRS jettisoned? Its components remain useful when considering infection but less so for 
identifying the sick septic patient. Outcome benefit from manual or automated SIRS-based screening 
tools is unproved [6]; despite increasing delivery of management bundles, rates of ICU transfer and 
mortality are unaltered. High rates of false positives and alert fatigue are also commonplace. A patient 
fulfilling every SIRS criterion may simply have a bad cold. What literature justifies antibiotics for 
patients with three or four SIRS criteria alone, with no evidence of organ involvement/dysfunction? 
In contrast, many patients admitted to ICUs have SIRS-negative infection-related organ failure [7, 8]. 
Reliance on SIRS is neither failsafe nor specific. 
Clinical markers of organ dysfunction underpin the rapid bedside quick Sepsis Related Organ Failure 
Assessment (qSOFA) tool to identify patients with possible sepsis and risk-prognosticate. We have 
stressed, however, that qSOFA requires prospective validation in varied healthcare settings [5]. 
The apparent inconsistency of mean blood pressure (BP) for shock and systolic BP for qSOFA is easily 
explained. Shock criteria were developed using the SSC database (systolic BP not recorded), and 
qSOFA from predominantly non-ICU-patient electronic health records where mean values were less 
frequently recorded. Pragmatically, systolic BP is more accurately and easily measured in non-ICU 
settings where qSOFA is intended; mean BP values are more accurate when electronically transduced. 
SOFA is not complex – it uses standard physiological/biochemical tests and takes under a minute to 
score. There is zero expectation, or requirement, to score SOFA daily, or when the  patient  presents. 
Though needing an update (a task for Sepsis-4?), SOFA is well validated and provides the universal 
structure presently lacking to quantify the deterioration in organ function related to an infection 
episode. Prior definitions failed to precisely describe what organ dysfunction is, leading to current 
epidemiological confusion. Only a modest change in SOFA (≥2 points), qualifying as ‘sepsis’, is 
associated with a significant mortality risk. Notwithstanding missing Glasgow Coma Scores or blood 
gases, this modest rise is easily noticed; deterioration is often considerably more than 2 points. 
SIRS criteria require blood tests (white count, blood gases) and thus equally challenging for low-
income countries. qSOFA is a bedside tool requiring only sphygmomanometer and watch. If 
respiratory rate is identified as important, hospitals can easily mandate routine recording at zero 
cost. A seven-point National Early Warning Score (notably, including all qSOFA criteria) is used across 
the UK [9] and, in general, successfully delivered. 
Sprung and colleagues fret that qSOFA may identify sick but not necessarily septic patients, leading to 
false alarms. Exactly the same applies to SIRS! Indeed, 50% of inpatients have ≥2 SIRS criteria at least 
once in their hospital stay, regardless of infection [10]. Are the authors not being self-contradictory? 
Surely we need to identify any sick patient, septic or otherwise, triggering a prompt summons to a 
clinical practitioner who can decide whether infection is causative. 
The ‘ugly’ allegations are far prettier than appreciated. The cited 1995 paper [11] oddly reports little  
difference in mortality between patients with (severe sepsis) and those without (sepsis) organ 
dysfunction. Claimed improvements in outcome [12] are actually based on data from patients with 
existing organ dysfunction, who likely have the ≥2 SOFA point rise to describe ‘new’ sepsis. This blank 
ammunition does not support the arguments of Sprung et al. about early recognition and treatment 
before organ dysfunction has developed, nor does the lack of outcome benefit from the SIRS 
screening studies [6]. 
Earlier identification of infected patients who may benefit from prompt treatment is clearly desirable. 
However, maintaining proportionality is key. Of 850,000 patients cultured and treated for suspected 
infection, only 5% died in hospital [13], often from non-infection causes. Critical care witnesses the 
severe tip of the infection iceberg. 
Sprung, Schein, and Balk also misunderstand the purpose of the shock definition (and clinical 
criteria). Like the mild‒moderate‒severe Berlin ARDS criteria [13], management should not differ 
depending on whether a sick patient falls within or outside the shock criteria thresholds. The “shock” 
criteria simply offer the necessary descriptor for more accurate coding and epidemiology. They are 
not intended as a clinical screening tool. 
 Sprung and co-authors fear mortality rates will be higher with Sepsis-3, precluding comparisons with 
old studies. As highlighted by our systematic review [4], between-study comparisons are already 
problematic. The proportion of patients dying will rise as the denominator shrinks, but the same 
number of patients will still die. 
Sepsis advances have been incremental rather than seismic. No magic therapeutic bullet exists, nor is 
one likely as we now recognize that sepsis is more than just systemic inflammation. This in itself 
justifies the need for a new definition that takes us forward from an outdated paradigm that has 
served its purpose. Using the old definitions as the basis of entry criteria into trials has failed to deliver 
the breakthroughs Dr. Sprung and colleagues bemoan. This too undermines their argument for 
maintaining the status quo. We need better diagnostics but these will catalyze updated definitions 
and descriptors, not vice versa. For now, we should apply current the understanding of pathogenesis 
and solid data to provide a relevant scientific basis, improve consistency, reliability, and 
generalizability, and enhance patient selection for trials. 
As per the recommendations of Sprung, Schein, and Balk, the big data analyses within Sepsis-3 have 
already compared the old and new criteria [14]. What randomized controlled trial can be performed 
on descriptors of a definition - what is being randomized? New biomarkers do need evaluation, but 
this is technology innovation upon which updated definitions will feed. We too recommended that 
SOFA be refined and a ‘SOFA-lite’ package developed for low-income nations [5]. Pending prospective 
validation, qSOFA could serve this purpose. 
 
Conflicts of interest 
None 
 
References 
1. Sprung CL, Schein RMH, Balk RA (2016) The new sepsis consensus definitions: the good, the bad and the ugly. 
Intensive Care Med. doi:10.1007/ s00134-016-4604-0 
2. Levy MM, Fink MP, Marshall JC et al (2003) 2001 SCCM/ESICM/ACCP/ ATS/SIS International Sepsis Definitions 
Conference. Intensive Care Med 31:530–538 
3. Shankar-Hari M, Phillips GS, Levy ML et al (2016) Developing a new definition and assessing new clinical 
criteria for septic shock: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). 
JAMA 315:775–787 
4. Kumar G, Kumar N, Taneja A et al (2011) Nationwide trends of severe sepsis in the 21st century (2000–2007). 
Chest 140:1223–1231 
5. Singer M, Deutschman CS, Seymour CW et al (2016) The third interna- tional consensus definitions for 
sepsis and septic shock (sepsis-3). JAMA 315:801–810 
6. Bhattacharjee P, Edelson DP, Churpek MM (2016) Identifying patients with sepsis on the hospital wards. Chest. 
doi:10.1016/j.chest.2016.06.020 
7. Kaukonen KM, Bailey M, Pilcher D, Cooper DJ, Bellomo R (2015) Systemic inflammatory response syndrome 
criteria in defining severe sepsis. N Engl J Med 372:1629–1638 
8. Shankar-Hari M, Harrison DA, Rowan KM (2016) Differences in impact of definitional elements on mortality 
precludes international comparisons of sepsis epidemiology: a cohort study illustrating the need for 
standard- ized reporting. Crit Care Med. doi:10.1097/CCM.0000000000001876 
9. Royal College of Physicians. National Early Warning Score (NEWS). https:// 
www.rcplondon.ac.uk/projects/outputs/national-early-warning-score- news (last accessed 8th Oct 2016) 
 
10. Churpek MM, Zadravecz FJ, Winslow C, Howell MD, Edelson DP (2015) Incidence and prognostic value of 
the systemic inflammatory response syndrome and organ dysfunctions in ward patients. Am J Respir Crit Care 
Med 192:958–964 
11. Rangel-Frausto MS, Pittet D, Costigan M et al (1995) The natural history of the systemic inflammatory 
response syndrome (SIRS). A prospective study. JAMA 273:117–123 
12. Levy MM, Rhodes A, Phillips GS et al (2014) Surviving Sepsis Campaign: association between performance 
metrics and outcomes in a 7.5-year study. Intensive Care Med 40:1623–1633 
13. The ARDS Definition Task Force (2012) Acute respiratory distress syndrome: the Berlin Definition. JAMA 
307:2526–2533 
14. Seymour CW, Liu VX, Iwashyna TJ et al (2016) Assessment of clinical criteria for sepsis: for the Third 
International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:762–774 
 
 
 
